Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Zahi I. Mitri"'
Autor:
Zahi I. Mitri, Nour Abuhadra, Shaun M. Goodyear, Evthokia A. Hobbs, Andy Kaempf, Alastair M. Thompson, Stacy L. Moulder
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-5 (2022)
Abstract Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity to enhance clinical management. We applied an Evolutionary Action Score to functionally characterize TP53 mutations (EAp53) in 9
Externí odkaz:
https://doaj.org/article/9f43d2c137084c2b949a03adf0c1d3b4
Autor:
Duygu Altinok Dindar, Brie Chun, Amy Palma, John Cheney, Madeline Krieger, Kristin Kasschau, Keaton Stagaman, Zahi I. Mitri, Shaun M. Goodyear, Jackilen Shannon, Lisa Karstens, Thomas Sharpton, Zhenzhen Zhang
Publikováno v:
Nutrients, Vol 15, Iss 21, p 4628 (2023)
Breast cancer (BCa) has many well-known risk factors, including age, genetics, lifestyle, and diet; however, the influence of the gut microbiome on BCa remains an emerging area of investigation. This study explores the connection between the gut micr
Externí odkaz:
https://doaj.org/article/d29d323960f44a70894f7d1ec1711186
Autor:
Marilyne Labrie, Allen Li, Allison Creason, Courtney Betts, Jamie Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R. Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annette Kolodzie, Paul T. Spellman, Jeremy Goecks, Lisa M. Coussens, Christopher L. Corless, Raymond Bergan, Joe W. Gray, Gordon B. Mills, Zahi I. Mitri
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
Abstract In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic s
Externí odkaz:
https://doaj.org/article/6f75a6bf3b4848219df5905c62072ab5
Autor:
Luai S. Al Rabadi, Madeline M. Cook, Andy J. Kaempf, Megan M. Saraceni, Michael A. Savin, Zahi I. Mitri
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Ado-trastuzumab (T-DM1), an antibody-drug c
Externí odkaz:
https://doaj.org/article/2659c47324254f67bf9628d1989ae754
Autor:
Allen Li, Jamie M. Keck, Swapnil Parmar, Janice Patterson, Marilyne Labrie, Allison L. Creason, Brett E. Johnson, Molly Downey, George Thomas, Carol Beadling, Laura M. Heiser, Annette Kolodzie, Alexander R. Guimaraes, Christopher L. Corless, Joe W. Gray, Gordon B. Mills, Raymond C. Bergan, Zahi I. Mitri
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract Molecular heterogeneity in metastatic breast cancer presents multiple clinical challenges in accurately characterizing and treating the disease. Current diagnostic approaches offer limited ability to assess heterogeneity that exists among mu
Externí odkaz:
https://doaj.org/article/8c98543d96874c89b755cdec2ccf84d0
Autor:
Zahi I. Mitri, Swapnil Parmar, Brett Johnson, Annette Kolodzie, Jamie M. Keck, Max Morris, Alexander R. Guimaraes, Brooke R. Beckett, Uma Borate, Charles D. Lopez, Kathleen A. Kemmer, Joshi J. Alumkal, Tomasz M. Beer, Christopher L. Corless, Gordon B. Mills, Joe W. Gray, Raymond C. Bergan
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background In order to establish the workflows required to implement a real-time process involving multi-omic analysis of patient samples to support precision-guided therapeutic intervention, a tissue acquisition and analysis trial was imple
Externí odkaz:
https://doaj.org/article/d768af7ba0ee4e3981e84981bb8e2ff1
Autor:
Malinda T West, Shaun M Goodyear, Evthokia A Hobbs, Andy Kaempf, Thomas Kartika, Jessica Ribkoff, Brie Chun, Zahi I Mitri
Publikováno v:
The Oncologist.
BackgroundCyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER−) metastatic breast cancer (MBC). However, next-
Autor:
Zahi I. Mitri, Evthokia A. Hobbs, Shaun M. Goodyear, Jeong Youn Lim, Joanna Pucilowska, Brett Johnson, Allison L. Creason, Courtney Betts, Lisa M. Coussens, Shannon McWeeney, Christopher L. Corless, Joe W. Gray, Gordon B. Mills
Publikováno v:
Cancer Research. 82:2149-2149
Background: Emerging data supports PARPi combinations, including PARPi with immune checkpoint blockade (ICB), as effective therapies in TNBC. The Adaptive Multi-Drug Treatment of Evolving Cancers (AMTEC) trial (NCT03801369) is evaluating the PARPi +
Autor:
Brie Chun, Duygu Altinok Dindar, Keaton Stagaman, Amy Palma, Erin Dahl, Kristin Kasschau, Shaun M. Goodyear, Zahi I. Mitri, Thomas Sharpton, Lisa Karstens, Zhenzhen Zhang
Publikováno v:
Cancer Research. 82:5927-5927
Background: Through diverse interactions with systemic immunosurveillance and metabolism, the gut microbiome is an important factor in the development and treatment of solid tumors including breast cancer (BC). The gut microbiome is also implicated i